• If you are wondering whether BioCryst Pharmaceuticals at US$9.40 still offers value, it helps to start by lining up the recent share performance with what the fundamentals suggest the stock might be worth.
• Over the short term, the share price return sits at 2.6% over 7 days, 24.0% over 30 days and 25.3% year to date, with a 20.5% return over 1 year and 9.8% over 3 years, compared with a 5 year return of a 7.6% decline.
• These moves are occurring as investors continue to respond to ongoing business developments and sector wide sentiment around smaller biotech names. This article is not tied to a specific event; instead, it takes those shifting expectations into account to help you judge whether the current price still lines up with the underlying worth of the business.
• Simply Wall St currently gives BioCryst Pharmaceuticals a valuation score of 5 out of 6. The next sections will walk through what that means by looking at different valuation approaches, before finishing with a broader way to think about value that goes beyond any single model.

Approach 1: BioCryst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and discounts them back to today, to estimate what the business might be worth in present value terms.

For BioCryst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow figure used is $344.33 million. Analyst inputs cover the earlier years of the forecast period, with Simply Wall St extrapolating further out to build a ten year path.

Within these projections, free cash flow in 2030 is modeled at $586.14 million, with the years between 2026 and 2035 stepping up from $113.82 million to $1.21 billion on the raw forecast line, before being discounted back to today. Summing those discounted values gives an estimated intrinsic value of about $77.96 per share.

Compared with the current share price of US$9.40, this DCF outcome suggests the shares trade at an 87.9% discount to that intrinsic estimate, which points to the stock being significantly undervalued on this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioCryst Pharmaceuticals is undervalued by 87.9%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: BioCryst Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for a share to the earnings that support it, which is often how many investors think about value in practice.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth and lower perceived risk can support a higher multiple, while slower growth or higher risk tends to justify a lower one.

BioCryst Pharmaceuticals currently trades on a P/E of 8.93x. That sits below the Biotechs industry average of 15.68x and the peer group average of 31.98x, which might initially make the stock look inexpensive relative to these broad benchmarks.

Simply Wall St’s proprietary “Fair Ratio” refines this picture by estimating what P/E might be appropriate after factoring in the company’s earnings growth profile, industry, profit margins, market cap and specific risks. Because it captures these fundamentals, the Fair Ratio of 19.67x can be more informative than a simple comparison with peers or the sector.

Set against the current P/E of 8.93x, the Fair Ratio points to BioCryst Pharmaceuticals trading on a lower multiple than this model would imply.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your BioCryst Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories you choose about BioCryst Pharmaceuticals. These stories connect your view of its products, risks and opportunities to a set of numbers on future revenue, earnings, margins and an assumed fair value.

On Simply Wall St’s Community page, Narratives let you pick or adjust a view. For example, you can choose a cautious outlook where fair value sits around US$13.00 with expectations for revenue to decline by 1.2% a year and profit margins to move toward 4.0%. Alternatively, you can select a far more optimistic view where fair value is closer to US$32.00 with modeled revenue growth of 17.18% and profit margins around 30.23%.

Each Narrative ties that story to a forecast and a fair value, then compares it with the current share price so you can judge for yourself whether the stock looks expensive or inexpensive on that set of assumptions. It also updates automatically when new data, news or earnings are added so your chosen view stays grounded in the latest information.

Do you think there's more to the story for BioCryst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.